Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 16, 2022 at 03:09 pm EST
Nymox Pharmaceutical Corporation reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 1.49 million compared to USD 3.3 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.04 a year ago.
For the nine months, net loss was USD 5.24 million compared to USD 9.73 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.12 a year ago. Diluted loss per share from continuing operations was USD 0.06 compared to USD 0.12 a year ago.